Mucin 17 Inhibitors

MUC17 Inhibitors are a broad class of compounds that can indirectly affect the expression or function of mucin 17 (MUC17), a type of glycoprotein that plays a significant role in the protective mucous barrier of the gastrointestinal tract. These compounds do not directly interact with MUC17. Instead, they influence the intricate cellular signaling networks that control the production and secretion of MUC17. Compounds such as gefitinib and erlotinib, which are epidermal growth factor receptor (EGFR) inhibitors, can lead to reduced signaling pathways that are implicated in the regulation of mucin genes, including MUC17. Inhibition of EGFR signaling can result in a decrease in mucin production, as EGFR is a known upregulator of mucin gene expression. Similarly, DNA methyltransferase inhibitors like 5-Azacytidine can modify the expression patterns of various genes by altering epigenetic marks, which may include those that control mucin production. Furthermore, agents such as curcumin and resveratrol impact a plethora of cellular mechanisms, and their wide-ranging effects can extend to the modulation of gene expression, including that of mucins. Nonsteroidal anti-inflammatory drugs (NSAIDs), represented by sulindac and indomethacin, can also modulate mucin production. These drugs are known to alter inflammatory pathways, which in turn can regulate the expression of mucins due to the close association between inflammation and mucosal barrier function. Other compounds, like the green tea polyphenol epigallocatechin gallate (EGCG), are recognized for their capacity to affect multiple signaling pathways and could alter mucin levels by these means. Collectively, these compounds represent a diverse arsenal of chemical agents that can modulate the cellular and molecular milieu in which MUC17 operates.